

# Endothelin-Induced Increased Aldosterone Activity Mediates Augmented Distal Nephron Acidification as a Result of Dietary Protein

Apurv Khanna,\* Jan Simoni,<sup>†</sup> and Donald E. Wesson\*<sup>‡</sup>

Departments of \*Internal Medicine, <sup>†</sup>Surgery, and <sup>‡</sup>Physiology, Texas Tech University Health Sciences Center, Texas Tech University School of Medicine, Lubbock, Texas

The hypothesis that increased dietary protein augments distal nephron acidification through endothelin-mediated increased aldosterone activity was tested. Munich-Wistar rats were studied after 3 wk of diets with 50% high protein (HiPro) and 20% control (CON) casein-provided protein, the latter comparable to standard diet. HiPro versus CON rats had higher distal nephron H<sup>+</sup> secretion by *in vivo* microperfusion as shown previously. Perfusion with inhibitors of Na<sup>+</sup>/H<sup>+</sup> exchange (EIPA, 10<sup>-5</sup> M), H<sup>+</sup>-ATPase (bafilomycin, 10<sup>-7</sup> M), and H<sup>+</sup>-K<sup>+</sup>-ATPase (Sch 28080 [10<sup>-5</sup> M] and ouabain [10<sup>-3</sup> M]) support that higher Na<sup>+</sup>/H<sup>+</sup> exchange and higher H<sup>+</sup>-ATPase but not higher H<sup>+</sup>-K<sup>+</sup>-ATPase activity mediated increased H<sup>+</sup> secretion in HiPro rats. Oral bosentan, an endothelin A/B receptor antagonist, decreased distal nephron H<sup>+</sup> secretion in HiPro rats as a result of reduced Na<sup>+</sup>/H<sup>+</sup> exchange and H<sup>+</sup>-ATPase activity as shown previously by the authors' laboratory. HiPro versus CON rats had higher plasma aldosterone (60.9 ± 5.9 versus 42.2 ± 4.4 pg/ml; *P* < 0.024) and higher urine aldosterone excretion (21.9 ± 3.9 versus 10.5 ± 2.8 ng/d; *P* < 0.04) in the absence but not presence of bosentan, consistent with endothelin-mediated increased aldosterone secretion. HiPro rats that did versus did not ingest the aldosterone antagonist spironolactone had lower distal nephron H<sup>+</sup> secretion (29.2 ± 3.3 versus 42.1 ± 3.8 pmol/mm per min; *P* < 0.05) as a result of lower H<sup>+</sup>-ATPase activity without differences in Na<sup>+</sup>/H<sup>+</sup> exchange or H<sup>+</sup>-K<sup>+</sup>-ATPase activity. The data support that dietary protein provided as casein increases distal nephron acidification through endothelin-stimulated Na<sup>+</sup>/H<sup>+</sup> exchange and endothelin-stimulated aldosterone secretion that increases H<sup>+</sup>-ATPase activity.

*J Am Soc Nephrol* 16: 1929–1935, 2005. doi: 10.1681/ASN.2004121054

Dietary acid as ammonium (NH<sub>4</sub><sup>+</sup>) salts augments distal nephron acidification (1,2) through endothelin-dependent mechanisms (3). Dietary intake of acid-producing protein also increases distal nephron acidification (4,5) by mechanisms that are also endothelin dependent (5). In the latter studies, augmented distal nephron acidification was due to an endothelin-mediated increase in both Na<sup>+</sup>/H<sup>+</sup> exchange and H<sup>+</sup>-ATPase activity (5). Endothelin stimulates Na<sup>+</sup>/H<sup>+</sup> exchange *in vitro* (6–8), but no studies report that endothelin increases *in vitro* H<sup>+</sup>-ATPase activity. Consequently, endothelin might stimulate H<sup>+</sup>-ATPase activity indirectly given the many endocrine alterations induced by a systemic acid challenge, including stimulation of the renin-angiotensin-aldosterone axis (9,10). Because increased dietary protein increases serum aldosterone (11), aldosterone increases distal nephron H<sup>+</sup>-ATPase activity (12), and endothelin infusion increases aldosterone secretion *in vivo* (13,14), the present studies tested the hypothesis that the endothelin-mediated increase in distal nephron H<sup>+</sup>-ATPase activity induced by acid-

producing dietary protein is due to increased aldosterone activity.

## Materials and Methods

### Animals and Diet Protocol

Male and female Munich-Wistar rats (Harlan Sprague-Dawley, Houston, TX; 200 to 220 g) ate standard rat chow (Prolab RMH 2500 with 23% protein) for 1 wk, then ate a custom minimum electrolyte diet with protein as purified high-nitrogen casein (ICN Nutritional Biochemicals, Cleveland, OH) for 3 wk. High protein (HiPro) and control (CON) rats ate 50 and 20% protein, respectively. In preliminary studies, similar-weight rats ate 24.6 ± 0.9 and 27.1 ± 1.2 g/d, respectively (*n* = 4, *P* = 0.15), so all rats received 24 g/d diet to ensure similar and complete intake. Some ingested bosentan (Actelion, Allschwil, Switzerland), a nonpeptide endothelin A/B receptor antagonist (15), mixed with study diet (100 mg/kg body wt per d). This oral dose blocks action of pressor doses of intravenous big endothelin-1 (ET-1) for >24 h (15). Others ingested spironolactone (400 mg/kg body wt per d) dissolved in olive oil and mixed with diet. This oral dose is in excess of that required for virtually complete mineralocorticoid receptor blockade *in vivo* (16). All drank distilled H<sub>2</sub>O *ad libitum*.

### Urine Net Acid and ET-1 Excretion

We measured daily urine net acid excretion (NAE) (17) and ET-1 (3) in a 24-h sample collected as described (5) from eight each of HiPro and CON rats in metabolic cages. We examined the effect of endothelin and aldosterone receptor blockade with bosentan and spironolactone, respectively, on urine NAE in paired and separate groups of eight each

Received December 7, 2004. Accepted March 22, 2005.

Published online ahead of print. Publication date available at [www.jasn.org](http://www.jasn.org).

Address correspondence to: Dr. Donald E. Wesson, Texas Tech University Health Sciences Center, Renal Section, 3601 Fourth Street, Lubbock, TX 79430. Phone: 806-743-3107; Fax: 806-743-3177; E-mail: [donald.wesson@ttuhsu.edu](mailto:donald.wesson@ttuhsu.edu)

(four with and four without drug) of HiPro and CON rats. NAE was the mean for each animal group.

### Arterial Blood Parameters

We measured pH,  $P_{\text{CO}_2}$ , calculated  $[\text{HCO}_3^-]$  (IRMA Blood Analysis System, Diametrics Medical, Inc., St. Paul, MN) and total  $\text{CO}_2$  ( $\text{TCO}_2$ ) by ultrafluorometry (see below) in 1.0 ml of blood from a chronic carotid arterial catheter in eight each of awake, gently restrained, and calm HiPro and CON rats to assess the effects of HiPro on plasma acid-base parameters. We also measured arterial BP through this chronic arterial catheter as done previously (18).

### Micropuncture Protocol

Animals were prepared for micropuncture of accessible distal tubules (19) at weeks 1 and 3. *In situ* early distal flow rate for HiPro and CON rats was  $9.4 \pm 0.7$  ( $n = 6$ ) and  $6.4 \pm 0.4$  nl/min ( $n = 8$ ), respectively. Separate superficial distal nephrons of HiPro and CON rats were each perfused 9 and 6 nl/min with a Hampel pump to approximate respective *in situ* flow rates. We measured distal tubule transepithelial potential difference to calculate blood-to-lumen  $\text{HCO}_3^-$  permeability (19). After the micropunctured (left) kidney was weighed, perfused nephron length was determined by measuring the length of a latex cast injected after micropuncture, recovered after acid digestion of the kidney (19). We measured  $[\text{HCO}_3^-]$  in stellate vessel plasma to determine peritubular blood-to-lumen  $\text{HCO}_3^-$  gradient for calculating transepithelial  $\text{H}^+/\text{HCO}_3^-$  passive permeability (19). Diet but not  $\text{H}_2\text{O}$  was withheld the evening before micropuncture to yield higher baseline  $\text{HCO}_3^-$  reabsorption (20), as done previously (19).

The perfusion solutions used are shown in Table 1. Solution 1 contained 5 mM  $\text{HCO}_3^-$  and 40 mM  $\text{Cl}^-$  to approximate their concentrations at the early distal nephron *in situ* (21). Solution 2 contained  $\text{Cl}^-$  but no  $\text{HCO}_3^-$  to measure  $\text{Cl}^-$ -dependent luminal  $\text{HCO}_3^-$  accumulation and to calculate an “apparent” blood-to-lumen  $\text{H}^+/\text{HCO}_3^-$  permeability (19). Solution 3 was  $\text{HCO}_3^-$ - and  $\text{Cl}^-$ -free and contained 0.5 mM acetazolamide to inhibit transtubule  $\text{H}^+/\text{HCO}_3^-$  transport and was used to determine “passive” blood-to-lumen  $\text{H}^+/\text{HCO}_3^-$  permeability (19). We used this passive permeability determined using solution 3 to calculate passive blood-to-lumen  $\text{HCO}_3^-$  secretion when perfusing with the  $\text{HCO}_3^-$ -containing solution 1 (19). We used the apparent blood-to-lumen  $\text{H}^+/\text{HCO}_3^-$  permeability determined from perfusing with solution 2 to calculate “total”  $\text{HCO}_3^-$  secretion when perfusing with  $\text{HCO}_3^-$ -containing solution 1 (19). We subtracted calculated passive  $\text{HCO}_3^-$  secretion from calculated total  $\text{HCO}_3^-$  secretion to obtain “net”  $\text{HCO}_3^-$  secretion when perfusing with solution 1 (19). The  $\text{HCO}_3^-$  secretion reported herein is the net  $\text{HCO}_3^-$  secretion that excludes the passive  $\text{HCO}_3^-$  secretion calculated as described above. Distal nephron  $\text{H}^+$  secretion was calculated by subtracting the calculated net  $\text{HCO}_3^-$  secretion (a negative value) from the measured net  $\text{HCO}_3^-$  reabsorption ( $\text{HCO}_3^-$

perfused into the distal nephron minus  $\text{HCO}_3^-$  collected) (18). All perfusing solutions contained raffinose to minimize fluid transport and gluconate substituted for  $\text{Cl}^-$  when necessary (19). Each surface distal nephron was perfused with each perfusing solution in the following order: 1, 2, 3. Previous studies showed that the order of perfusing solutions did not affect calculations of the components of distal nephron  $\text{HCO}_3^-$  reabsorption (19).

### Identification of $\text{H}^+$ Transport Mediators of HiPro-Induced Changes in Distal Nephron Acidification

We compared the net decrease in distal nephron  $\text{H}^+$  secretion in response to specific  $\text{H}^+$  transport inhibitors to determine contributions of individual distal nephron  $\text{H}^+$  transporters to differences in overall distal nephron  $\text{H}^+$  secretion in HiPro *versus* CON rats. The contribution of  $\text{Na}^+/\text{H}^+$  exchange and  $\text{H}^+$ -ATPase was determined by perfusing with solutions that contained EIPA ( $10^{-5}$  M) and bafilomycin ( $10^{-7}$  M), respectively, as done previously in our laboratory (22). Because the rat renal cortex contains the gastric isoform of  $\text{H}^+-\text{K}^+$ -ATPase (23), we perfused tubules with Sch 28080 ( $10^{-5}$  M) to inhibit this transporter (24) and determine whether its activity was increased in HiPro rats. Although the colonic isoform of  $\text{H}^+-\text{K}^+$ -ATPase has not been identified in the rat renal cortex (25) and its presence has not been induced by dietary  $\text{NH}_4\text{Cl}$  (25), we additionally perfused distal nephrons with solutions that contained both Sch 28080 ( $10^{-5}$  M) and ouabain ( $10^{-3}$  M), the latter inhibiting the colonic  $\text{H}^+-\text{K}^+$ -ATPase isoform (24). The latter perfusion was done to determine whether HiPro induced and/or increased activity of either the gastric or colonic  $\text{H}^+-\text{K}^+$ -ATPase isoforms. Greater inhibitor-induced decrease in  $\text{H}^+$  secretion in HiPro *versus* CON rats determined increased activity of the  $\text{H}^+$  transporter inhibited by that compound (22).

### Analytical Methods

Immediately after experiment termination, initial and collected perfusate and stellate vessel plasma samples were analyzed for inulin (19) and for  $\text{TCO}_2$  using flow-through ultrafluorometry (26) as described previously (27). All tubule fluid and plasma  $\text{TCO}_2$  were measured on the experimental day by comparing fluorescence of a 7- to 8-ml sample aliquot (corrected for a distilled  $\text{H}_2\text{O}$  blank run with each sample group) with a standard curve as described previously (27). This technique actually measures  $\text{TCO}_2$ , but we refer to this measured value as  $\text{HCO}_3^-$  for simplicity.

### Statistical Analyses

Data were expressed as means  $\pm$  SEM. One to two distal nephron segments were perfused per animal. When two tubules were perfused in an animal, results were meaned to yield a single value for that animal. Group number is number of animals. Paired perfusions of the same tubule were compared using paired *t* test; otherwise, ANOVA was used for multiple group comparisons. We used the Bonferroni method for multiple comparisons ( $P < 0.05$ ) of the same parameter among groups.

## Results

### Effect of HiPro and Receptor Antagonists on Animal/Kidney/Tubule Growth

The HiPro protocol increases body and kidney weight as well as the length of the accessible distal tubule (5). Neither the endothelin A/B receptor antagonist bosentan nor the mineralocorticoid antagonist spironolactone affected animal/kidney weight, tubule length, food intake, or urine output in either group.

Table 1. Perfusate composition (mM)

	Solution 1	Solution 2	Solution 3
$\text{Na}^+$	61	61	61
$\text{K}^+$	4	4	4
$\text{Cl}^-$	40	40	0
$\text{HCO}_3^-$	5	0	0
Gluconate	20	25	65
Acetazolamide	0	0	0.5
Raffinose	200	200	200

### Effect of HiPro on Arterial Acid-Base Parameters of Conscious Animals

Table 2 shows that HiPro compared with CON arterial pH,  $P_{CO_2}$ , and calculated  $[HCO_3^-]$  by blood gases were not different but plasma  $TCO_2$  by ultrafluorometry was lower in HiPro. Mean BP (MBP) was not different in HiPro and CON rats ( $111.5 \pm 2.4$  versus  $108.3 \pm 2.1$  mmHg;  $P = 0.33$ ;  $n = 8$  animals each).

### Effect of HiPro on Renal Acidification

HiPro rats have higher urine NAE than CON rats mediated by higher urine  $NH_4^+$  and lower  $HCO_3^-$  excretion with similar excretion of titratable acid (5). Distal nephron net  $HCO_3^-$  reabsorption was higher in HiPro than CON rats perfused at 6 and 9 nl/min as a result of higher  $H^+$  secretion and to less extent to lower  $HCO_3^-$  secretion (5).

### Transport Mediators of Enhanced Distal Nephron Acidification in HiPro Rats

Figure 1 shows greater net decrease in distal nephron  $H^+$  secretion in HiPro than in CON rats with EIPA ( $-15.5 \pm 1.0$  versus  $-10.5 \pm 0.9$  pmol/mm per min [ $P < 0.003$  at 6 nl/min,  $n = 8$  animals each] and  $-15.9 \pm 1.1$  versus  $-9.8 \pm 0.9$  pmol/mm per min [ $P < 0.001$  at 9 nl/min,  $n = 8$  animals each]) and bafilomycin ( $-14.5 \pm 1.1$  versus  $-7.7 \pm 0.6$  pmol/mm per min [ $P < 0.001$  at 6 nl/min,  $n = 8$  animals each] and  $-12.4 \pm 1.0$  versus  $-6.1 \pm 0.9$  pmol/mm per min [ $P < 0.001$  at 9 nl/min,  $n = 8$  animals each]), consistent with enhanced  $Na^+/H^+$  exchange and increased  $H^+$ -ATPase activity, respectively. Neither Sch 28080-induced ( $-3.4 \pm 0.9$  versus  $-2.8 \pm 0.8$  pmol/mm per min [ $P = 0.52$  at 6 nl/min,  $n = 8$  animals each] and  $-4.0 \pm 0.8$  versus  $-3.3 \pm 0.7$  pmol/mm per min [ $P = 0.29$  for 9 nl/min,  $n = 8$  animals each]) or Sch 28080+ouabain-induced ( $-3.1 \pm 1.0$  versus  $-1.8 \pm 0.9$  pmol/mm per min [ $P = 0.37$  at 6 nl/min,  $n = 4$  animals each] and  $-3.5 \pm 0.9$  versus  $-2.7 \pm 0.8$  pmol/mm per min [ $P = 0.53$  for 9 nl/min,  $n = 4$  animals each]) net decrease in  $H^+$  secretion differed in HiPro and CON rats, consistent with no increased  $H^+-K^+$ -ATPase activity in HiPro rats.

### Effect of HiPro on Renal ET-1 and Aldosterone Production

HiPro increases urine ET-1 excretion, ET-1 addition to renal cortical microdialysate, and renal cortical mRNA (5). Figure 2 shows that HiPro compared with CON rats had higher plasma aldosterone ( $60.9 \pm 5.9$  versus  $42.2 \pm 2.4$  pg/ml;  $P = 0.033$ , ANOVA;  $n = 8$  animals each) and higher urine aldosterone excretion ( $21.9 \pm 3.5$  versus  $10.5 \pm 1.8$  ng/d;  $P = 0.035$ , ANOVA;  $n = 8$  animals each) in the absence of bosentan. By contrast,

plasma aldosterone ( $51.4 \pm 4.9$ ;  $P = 0.34$  versus CON;  $n = 8$  animals) and urine aldosterone excretion ( $13.0 \pm 2.7$ ;  $P = 0.45$  versus CON;  $n = 8$  animals) were not different between bosentan-ingesting HiPro and CON rats, respectively.

### Effect of Endothelin and Mineralocorticoid Receptor Blockade on Arterial Blood and Urine Parameters

Bosentan did not affect CON arterial plasma acid-base parameters (data not shown). Plasma  $TCO_2$ , urine net NAE, and MBP were not different in HiPro rats that did compared with did not ingest bosentan (5). By contrast, CON rats that ingested spironolactone had lower plasma  $TCO_2$  than concurrently studied CON rats that did not ingest spironolactone ( $22.9 \pm 0.6$  versus  $25.2 \pm 0.6$  mM;  $P = 0.017$ ;  $n = 8$  animals each) but similar urine NAE ( $3569 \pm 448$  versus  $4460 \pm 639$   $\mu$ M/d;  $P = 0.27$ ;  $n = 8$  animals each) and MBP ( $107.8 \pm 2.2$  versus  $110.1 \pm 2.2$  mmHg;  $P = 0.74$ ;  $n = 8$  animals each). Similarly, HiPro rats that did compared with concurrently studied HiPro rats that did not ingest spironolactone had lower plasma  $TCO_2$  ( $20.2 \pm 0.8$  versus  $23.0 \pm 0.5$  mM;  $P = 0.02$ ;  $n = 8$  animals each) but similar urine NAE ( $6210 \pm 589$  versus  $7067 \pm 937$   $\mu$ M/d;  $P = 0.45$ ;  $n = 8$  animals each) and MBP ( $110.7 \pm 2.2$  versus  $111.5 \pm 2.4$  mmHg;  $P = 0.81$ ;  $n = 8$  animals each).

### Effect of Endothelin and Mineralocorticoid Receptor Blockade on HiPro-Induced Augmented Distal Nephron Acidification

Distal nephron acidification was not different between CON rats that did and did not receive bosentan (5). Similarly, distal nephron net  $HCO_3^-$  reabsorption was not different between CON rats that did and did not receive spironolactone whether perfused at 6 nl/min ( $10.8 \pm 1.7$  versus  $12.9 \pm 1.4$  pmol/mm per min, respectively;  $P = 0.36$ ;  $n = 8$  animals each) or 9 nl/min ( $12.8 \pm 1.9$  versus  $14.9 \pm 1.4$  pmol/mm per min;  $P = 0.39$ ;  $n = 8$  animals each). By contrast, HiPro rats that did compared with did not receive bosentan had lower distal tubule net  $HCO_3^-$  reabsorption that was mediated by lower  $H^+$  secretion and higher  $HCO_3^-$  secretion (5). Similarly, Figure 3 shows that HiPro rats that did compared with did not receive spironolactone had lower distal nephron net  $HCO_3^-$  reabsorption ( $26.7 \pm 3.0$  versus  $39.0 \pm 3.1$  pmol/mm per min;  $P < 0.013$ ;  $n = 8$  animals each). Like the decreased distal nephron net  $HCO_3^-$  reabsorption as a result of bosentan, the decreased distal nephron net  $HCO_3^-$  reabsorption as a result of spironolactone was mediated by reduced  $H^+$  secretion ( $29.2 \pm 3.3$  versus  $42.1 \pm 3.8$  pmol/mm per min;  $P < 0.023$ ;  $n = 8$  animals each). Unlike decreased distal nephron net  $HCO_3^-$  reabsorption induced by bosentan that was also mediated by increased distal nephron  $HCO_3^-$  secretion (5),

Table 2. Plasma acid-base data in conscious animals after 3 weeks of dietary protein<sup>a</sup>

	pH	$P_{CO_2}$ (mmHg)	Calculated $[HCO_3^-]$ (mM)	Measured $[TCO_2]$ (mM)
CON (20% protein; $n = 8$ )	$7.41 \pm 0.02$	$39.2 \pm 1.0$	$24.1 \pm 0.9$	$25.2 \pm 0.6$
HiPro (50% protein; $n = 8$ )	$7.38 \pm 0.02$	$38.5 \pm 1.0$	$22.1 \pm 0.8$	$23.3 \pm 0.5^b$

<sup>a</sup>Values are means  $\pm$  SEM. CON, control; HiPro, 3 wk of 50% dietary protein;  $TCO_2$ , total  $CO_2$ .

<sup>b</sup> $P < 0.05$  versus 20% protein.




Figure 1. Net change in distal nephron proton ( $H^+$ ) secretion in response to *in vivo* microperfusion at 6 or 9 nl/min with inhibitors of  $Na^+/H^+$  exchange (EIPA),  $H^+$ -ATPase (bafilomycin), gastric  $H^+-K^+$ -ATPase (Sch 28080), and gastric + colonic  $H^+-K^+$ -ATPase (Sch 28080 + ouabain). \* $P < 0.05$  versus control (CON).




Figure 2. Plasma aldosterone (left) and urine aldosterone excretion (right) in CON, HiPro, and HiPro animals that received the endothelin A/B receptor antagonist bosentan. \* $P < 0.05$  versus CON.

this component of distal nephron net  $HCO_3^-$  reabsorption was not different in HiPro rats that did compared with did not ingest spironolactone ( $-5.4 \pm 0.6$  versus  $-3.9 \pm 0.7$  pmol/mm per min;  $P = 0.13$ ;  $n = 8$  animals each).

#### Effect of Endothelin and Mineralocorticoid Receptor Blockade on Enhanced $H^+$ Transporter Activity Induced by HiPro

Net decrease in distal nephron  $H^+$  secretion was not different in bosentan-ingesting compared with noningesting HiPro rats that were perfused at 9 nl/min with EIPA and bafilomycin, consistent with no additional effect of these inhibitors on  $Na^+/H^+$  exchange and  $H^+$ -ATPase activity, respectively, in HiPro rats with endothelin A/B receptor blockade (5). There was also no difference in the net decrease in  $H^+$  secretion in bosentan-ingesting compared with noningesting HiPro rats that were perfused with Sch 28080 (5), consistent with no effect of endothelin A/B receptor blockade on  $H^+-K^+$ -ATPase activ-

ity in HiPro rats. By contrast, Figure 4 shows that spironolactone-ingesting compared with noningesting HiPro rats had less bafilomycin-induced decrease in distal nephron  $H^+$  secretion when perfused at 9 nl/min ( $-6.5 \pm 1.2$  versus  $-14.5 \pm 1.1$  pmol/mm per min;  $P < 0.001$ ;  $n = 8$  animals each), consistent with spironolactone-induced inhibition of the previously demonstrated augmented  $H^+$ -ATPase activity of HiPro rats. By contrast, EIPA-induced ( $-13.2 \pm 1.4$  versus  $-15.9 \pm 1.1$  pmol/mm per min;  $P = 0.15$  at 9 nl/min;  $n = 8$  animals each), Sch 28080-induced ( $-6.1 \pm 0.9$  versus  $-4.0 \pm 0.8$  pmol/mm per min;  $P = 0.10$  at 9 nl/min;  $n = 8$  animals each), and Sch 28080 + ouabain-induced ( $-8.9 \pm 1.6$  versus  $-6.6 \pm 0.9$  pmol/mm per min;  $P = 0.26$  at 9 nl/min;  $n = 4$  animals each) decrease in distal nephron  $H^+$  secretion was not different in spironolactone-ingesting compared with noningesting HiPro rats, consistent with no spironolactone effect on  $Na^+/H^+$  exchange or  $H^+-K^+$ -ATPase activity, respectively, in HiPro rats.




Figure 3. Distal tubule net HCO<sub>3</sub> reabsorption (Net J<sub>HCO<sub>3</sub></sub>) and its components HCO<sub>3</sub> and H<sup>+</sup> secretion by *in vivo* microperfusion in HiPro-non-ingesting and -ingesting the aldosterone receptor antagonist spironolactone. \*P < 0.05 versus CON.

### Discussion

These studies tested the hypothesis that the endothelin-dependent increase in distal nephron H<sup>+</sup>-ATPase activity in HiPro rats (5) is mediated through endothelin-stimulated aldosterone secretion that enhances H<sup>+</sup>-ATPase activity. HiPro as casein was associated with increases of plasma aldosterone and urine aldosterone excretion in the absence but not presence of the endothelin A/B receptor antagonist bosentan. Furthermore, reduction in distal nephron H<sup>+</sup> secretion induced by the H<sup>+</sup>-ATPase inhibitor bafilomycin was less in the presence than absence of the aldosterone receptor antagonist spironolactone in HiPro rats. Together, the present studies support that HiPro as casein induces endothelin-stimulated secretion of aldosterone that increases distal nephron H<sup>+</sup>-ATPase activity. Because increased dietary protein induces endothelin-mediated increased distal nephron Na<sup>+</sup>/H<sup>+</sup> exchange (5), augmented H<sup>+</sup> secretion induced by HiPro is mediated by the combined effects of endothelin and aldosterone.

Increased intake of dietary protein that is composed of acid-producing amino acids increases metabolic acid production and renal acid excretion (28) that is mediated by augmented distal nephron acidification (4,5). Augmented distal nephron acidification is manifest by increased net

HCO<sub>3</sub> reabsorption (29), consistent with increased H<sup>+</sup> secretion that reclaims filtered HCO<sub>3</sub> and promotes NH<sub>4</sub><sup>+</sup> secretion (30). The resulting decrease in HCO<sub>3</sub> delivery to the terminal nephron also promotes NH<sub>4</sub><sup>+</sup> secretion (30) and permits secreted H<sup>+</sup> to titrate non-HCO<sub>3</sub> buffers that effect net acid excretion rather than HCO<sub>3</sub> reclamation (31). Previous studies showed that the augmented distal nephron H<sup>+</sup> secretion induced by HiPro is due to increased Na<sup>+</sup>/H<sup>+</sup> exchange and increased H<sup>+</sup>-ATPase activity (5). The previous (5) and present studies support that this enhanced Na<sup>+</sup>/H<sup>+</sup> exchange and H<sup>+</sup>-ATPase activity is mediated by endothelin and aldosterone, respectively. Augmented distal nephron acidification induced by dietary acid is also due to decreased distal nephron HCO<sub>3</sub> secretion (2), again through an endothelin-dependent mechanism (3). Endothelin infusion decreases distal nephron HCO<sub>3</sub> secretion (32), but whether this effect is direct or is mediated through another agent was not determined. Consequently, endothelins play an important role in mediating both the increased H<sup>+</sup> secretion and decreased HCO<sub>3</sub> secretion induced by dietary acid that mediate the increased distal nephron acidification in this setting.

Spironolactone was used as the aldosterone antagonist in the present studies to demonstrate the aldosterone-mediated increase in distal nephron H<sup>+</sup>-ATPase activity. Other investigators re-




Figure 4. Net change in distal nephron proton (H<sup>+</sup>) secretion in HiPro response to *in vivo* microperfusion at 9 nl/min with inhibitors of Na<sup>+</sup>/H<sup>+</sup> exchange (EIPA), H<sup>+</sup>-ATPase (bafilomycin), and H<sup>+</sup>-K<sup>+</sup>-ATPase (Sch 28080). \*P < 0.05 versus HiPro.

ported studies supporting that spironolactone increases endogenous acid production (33) that might have contributed to the decrease in plasma  $\text{TCO}_2$  observed in both HiPro and CON animals that ingested spironolactone. The microperfusion studies reported in the present studies nevertheless support that aldosterone-mediated increased  $\text{H}^+$ -ATPase activity contributed to the augmented  $\text{H}^+$  secretion of HiPro animals.

The mechanisms by which dietary acid as  $\text{NH}_4^+$  salts (3) or as acid-producing dietary protein (4,5) increases renal endothelin production and cell type that is the endothelin source are not clear. Renal microvascular endothelial cells that are exposed to an acid extracellular environment *in vivo* increase ET-1 release into the culture medium (34), possibly contributing to increased renal interstitial fluid ET-1 levels in response to dietary acid (3). Nevertheless, renal epithelial cells also make and secrete ET-1 (35) and might also be a source of the augmented renal endothelin. The present studies support that the increased plasma and urine aldosterone associated with HiPro was mediated by endothelin. Similarly, chronic dietary  $\text{NH}_4\text{Cl}$  increases plasma aldosterone (36), and endothelin might also mediate the increased plasma aldosterone that occurs in this setting. Endothelin infusion increases aldosterone secretion in rats *in vivo* (13,14), and endothelin is an important paracrine regulator of zona glomerulosa function (37).

In summary, HiPro as purified casein augments distal nephron  $\text{H}^+$  secretion through aldosterone-stimulated increased  $\text{H}^+$ -ATPase activity. The increased aldosterone in this setting is mediated through endothelin, which itself increases distal nephron  $\text{Na}^+/\text{H}^+$  exchange. The data support that aldosterone and endothelins are important mediators of the increased distal nephron acidification associated with increased intake of dietary protein, the common dietary challenge to systemic acid-base homeostasis faced by humans.

## Acknowledgments

This work was supported by funds from the Larry and Jane Woirhay Memorial Endowment in Renal Research, the Texas Tech University Health Sciences Center.

We are grateful to Jeri Tasby and Cathy Hudson for expert technical assistance.

## References

- Levine DZ: An *in vivo* microperfusion study of distal tubule bicarbonate reabsorption in normal and ammonium chloride rats. *J Clin Invest* 75: 588–595, 1985
- Wesson DE: Reduced  $\text{HCO}_3^-$  secretion mediates increased distal nephron acidification induced by dietary acid. *Am J Physiol* 271: F670–F678, 1996
- Wesson DE: Endogenous endothelins mediate increased distal tubule acidification induced by dietary acid in rats. *J Clin Invest* 99: 2203–2211, 1997
- Kunau RT, Walker KA: Total  $\text{CO}_2$  absorption in the distal tubule of the rat. *Am J Physiol* 252: F468–F473, 1987
- Khanna A, Simoni J, Hacker C, Duran M-J, Wesson DE: Increased endothelin activity mediates augmented distal nephron acidification induced by dietary protein. *J Am Soc Nephrol* 15: 2266–2275, 2004
- Eiam-Ong S, Hilden SA, King AJ, Johns CA, Madias NE: Endothelin-1 stimulates the  $\text{Na}^+/\text{H}^+$  and  $\text{Na}^+/\text{HCO}_3^-$  transporters in rabbit renal cortex. *Kidney Int* 42: 18–24, 1992
- Guntupalli J, DuBose TD Jr: Effects of endothelin on rat proximal tubule  $\text{Na}^+/\text{Pi}$  cotransport and  $\text{Na}^+/\text{H}^+$  exchange. *Am J Physiol* 266: F685–F666, 1994
- Chu T-S, Peng Y, Cano A, Yanagisawa M, Alpern RJ: EndothelinB receptor activates NHE-3 by a  $\text{Ca}^{2+}$ -dependent pathway in OKP cells. *J Clin Invest* 97: 1454–1462, 1996
- Schambelan M, Sebastian A, Katuna A, Arteaga E: Adrenocortical hormone secretory response to chronic  $\text{NH}_4\text{Cl}$ -induced metabolic acidosis. *Am J Physiol* 252: E454–E460, 1987
- Henger A, Tutt P, Riesen WF, Hulter HN, Krapf R: Acid-base and endocrine effects of aldosterone and angiotensin II inhibition in metabolic acidosis in human patients. *J Lab Clin Med* 136: 379–389, 2000
- Seney F, Marver D: Protein intake and cation transport in the loop of Henle. *J Lab Clin Med* 114: 587–594, 1989
- Eiam-Ong S, Kurtzman NA, Sabatini S: Regulation of collecting tubule adenosine triphosphatases by aldosterone and potassium. *J Clin Invest* 91: 2385–2392, 1993
- Pecci A, Gomez-Sanchez CE, de Bedners ME, Lantos CP, Cozza EN: *In vivo* stimulation of aldosterone biosynthesis by endothelin: Loci of action and effects of dose and infusion rate. *J Steroid Biochem Mol Biol* 45: 555–561, 1995
- Mazzocchi G, Rebuffat P, Gottardo G, Meneghelli V, Nussdorfer GG: Evidence that both ETA and ETB receptor subtypes are involved in the *in vivo* aldosterone secretagogue effect of endothelin-1 in rats. *Res Exp Med* 196: 145–152, 1996
- Clozel M, Brey V, Gray G, Kalina B, Loffler B-M, Burri K, Cassal J-M, Hirth G, Muller M, Neidhart W, Ramuz H: Pharmacological characterization of Bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. *J Pharmacol Exp Ther* 270: 228–235, 1994
- deGasparo M, Joss U, Ramjouw HP, Whitebread SE, Haenni G, Schenkel L, Kraehenbuehl C, Biollaz, Grob J, Schmidlin J: Three new epoxy-spironolactone derivatives: Characterization *in vivo* and *in vitro*. *J Pharmacol Exp Ther* 240: 65–656, 1987
- Wesson DE: Dietary bicarbonate reduces rat distal nephron acidification evaluated *in situ*. *Am J Physiol* 258: F870–F876, 1990
- Wesson DE: Endogenous endothelins mediate augmented acidification in remnant kidneys. *J Am Soc Nephrol* 12: 1826–1835, 2001
- Wesson DE, Dolson GM: Augmented bidirectional  $\text{HCO}_3^-$  transport by rat distal tubules in chronic alkalosis. *Am J Physiol* 261: F308–F317, 1991
- Levine DZ, Iacovitti M, Nash L, Vandorpe D: Secretion of bicarbonate by rat distal tubules *in vivo*. Modulation by overnight fasting. *J Clin Invest* 81: 1873–1878, 1988
- Wesson DE: Depressed distal tubule acidification corrects chloride-deplete alkalosis in rats. *Am J Physiol* 259: F636–F644, 1990
- Wesson DE:  $\text{Na}^+/\text{H}^+$  exchange mediates increased distal tubule acidification in chronic alkalosis. *Kidney Int* 53: 945–951, 1998
- Ahn KY, Turner PB, Madsen KM, Kone BC: Effects of chronic hypokalemia on renal expression of the “gastric”  $\text{H}^+/\text{K}^+$ -ATPase alpha-subunit gene. *Am J Physiol* 274: F557–F566, 1996

24. Nakamura S, Wang Z, Galla JH, Soleimani M: K<sup>+</sup> depletion increases HCO<sub>3</sub> reabsorption in OMCD by activation of colonic H<sup>+</sup>-K<sup>+</sup>-ATPase. *Am J Physiol* 270: F687–F692, 1998
25. Codina J, Delmas-Mata JT, Dubose TD Jr: Expression of HKalpha2 protein is increased selectively in renal medulla by chronic hypokalemia. *Am J Physiol* 275: F433–F440, 1998
26. Star RA: Quantitation of total carbon dioxide in nanoliter samples by flow-through fluorometry. *Am J Physiol* 258: F429–F432, 1990
27. Wesson DE: Dietary HCO<sub>3</sub> reduces distal tubule acidification by increasing cellular HCO<sub>3</sub> secretion. *Am J Physiol* 271: F132–F142, 1996
28. Remer T: Influence of nutrition on acid-base balance-metabolic aspects. *Eur J Nutr* 40: 214–220, 2001
29. Atkins JL, Burg MB: Bicarbonate transport by isolated perfused rat cortical collecting ducts. *Am J Physiol* 249: F485–F489, 1985
30. Knepper MA, Packer R, Good DW: Ammonium transport in the kidney. *Physiol Rev* 69: 179–248, 1989
31. Buerkert J, Martin D, Trigg D: Segmental analysis of the renal tubule in buffer production and net acid formation. *Am J Physiol* 244: F442–F445, 1983
32. Wesson DE, Dolson GM: Endothelin-1 increases rat distal tubule acidification in vivo. *Am J Physiol* 273: F586–F594, 1997
33. Hulter HN, Bonner EL Jr, Glynn RD, Sebastian A: Renal and systemic acid-base effects of chronic spironolactone administration. *Am J Physiol* 240: F381–F387, 1981
34. Wesson DE, Simoni J, Green DF: Reduced extracellular pH increases endothelin-1 secretion by human renal microvascular cells. *J Clin Invest* 101: 578–583, 1998
35. Kohan DE: Endothelin synthesis by rabbit renal tubule cells. *Am J Physiol* 261: F221–F226, 1991
36. Thompson A, Bailey MA, Micheal AE: Effects of changes in dietary intake of sodium and potassium and of metabolic acidosis on 11beta-hydroxycorticoid dehydrogenase activities in rat kidney. *Exp Nephrol* 8: 44–51, 2000
37. Nussdorfer GG, Rossi GP, Belloni AS: The role of endothelins in the paracrine control of the secretion and growth of the adrenal cortex. *Rev Cytol* 171: 267–308, 1997